| Identification | Back Directory | [Name]
DC0-NH2 | [CAS]
615538-51-7 | [Synonyms]
DC0-NH2
1H-Indole-2-carboxamide, 5-amino-N-[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]- | [Molecular Formula]
C31H24ClN5O3 | [MOL File]
615538-51-7.mol | [Molecular Weight]
550.01 |
| Chemical Properties | Back Directory | [Boiling point ]
847.6±65.0 °C(Predicted) | [density ]
1.537±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
9.47±0.40(Predicted) | [color ]
Light brown to brown |
| Hazard Information | Back Directory | [Uses]
DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component[1]. | [IC 50]
Duocarmycins | [References]
[1] Zhao RY, et al. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.J Med Chem. 2012 Jan 26;55(2):766-82. DOI:10.1021/jm201284m |
|
|